GOG-0275

Terminated

Return to Protocol Table

A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-Day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia

Principal Investigator

Julian Schink

Status

Terminated

Open to Accrual

June 18, 2012

Closed to Accrual

September 20, 2016

Closed to Accrual & Treatment

July 17, 2020

Complete

July 17, 2020

Terminated

July 17, 2020


Disease Site

Gynecologic [GY] Other

Phase

III

Developmental Therapeutics

No

Primary Objective

To test the hypothesis that treatment with multi-day methotrexate is inferior to treatment with pulse actinomycin-D in patients with low-risk gestational trophoblastic disease with respect to complete response.

Patient Population

Patients who meet F.I.G.O. Stage I, II, or III criteria for low-risk gestational trophoblastic neoplasia (GTN): post molar GTN or choriocarcinoma.

Target Accrual

381

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.